Tariff recovery underway; core margin positive but patchy near-term

Operating profit ₹3.43Cr (Q1 FY27) vs ₹0.28Cr (Q1 FY26), 12-fold jump on flat revenue

₹32.24Cr (Q1 FY27) vs ₹33.39Cr (Q1 FY26), down 3.4% but Q1 FY25 was ₹29.21Cr (+10.3% QoQ)

PAT ₹7.12Cr (+153% YoY) but ₹7.11Cr of the ₹7.11Cr other income is non-recurring (FX gains, unrealized fair value gains)

₹14.72Cr cost of materials / ₹32.24Cr revenue = 45.6%, improvement from ~48% prior year

Direct quote: 'I think it will be about 70% concentrated in the top 5 clients'

Stated on call; management clarified this is pieces-based, not floor-based metric

Operating profit jumped 12x (₹0.28→₹3.43Cr) on same revenue, signaling prior-year tariff/operational stress is easing.

US share dropped from 50% to 40% due to tariff drag and customer overstocking. Europe now ~60%. Customer retention confirmed but volume hit real.

Patent dispute with SHORTSTOP brand; test marketing paused. No timeline to restart.

Sri Lanka MOU signed for tariff hedging (contingency only). Nepal and Vietnam under evaluation for future factory or contract manufacturing.

Tariff impact on selling price is uniform; premium's advantage is in product complexity and customer retention, not tariff pass-through. We retained customers by sharing burden; low-cost peers couldn't.

70% capacity utilization expected; margins moving back towards FY25 levels (pre-tariff). EBITDA margin targeting ~17% by FY28.

50-50 Europe/US historically; now ~60% Europe, 40% US due to tariffs. Tariff levels not back to normal but customer relationships intact. Volumes reduced, blend of tariff + overstocking.

Conservative figure. FTAs not yet operational (EU Q1 CY27, US uncertain). We're hopeful to surpass. FY25 had 12.5Cr exceptional land sale; adjusting for that, EBITDA was ~38Cr, so guidance is cautious.

Top 5: ~70%. Top 10: >95%. We have 12–20 customers at any point. Large customer base is concentrated but relationships are long-standing.

Entered test phase, then paused due to patent dispute with SHORTSTOP brand. Not heavily invested yet; on hold until patent issue resolved.

Partnered with customers on discounts to hedge cost increases. Held shipments to land at favorable tariff windows. Margin took hit but customer retention was priority.

₹40–50Cr phased: ₹20Cr per factory. First factory operational ~FY28, second ~FY30. Product mix and demand will drive exact timing.

Not quantified. EU FTA expected Q1 CY27; US ongoing with contradictory reports. Premium positioning gives us advantage but can't predict exact uplift.

No. Domestic brands are price-driven, don't value our quality/compliance setup. Margins lower, not worth focus. Export-oriented model is core.

70% capacity target (vs 65% now). Revenue growth contingent on US tariff normalization & demand pickup.

Admits this is conservative; assumes FTA benefits roll in and geopolitical stability. Current tailwind (China Plus One) not yet reflected in orders.

Vague framing. Q1 FY27 core EBITDA 3.4% is still far from 33%; 'back to pre-tariff' unclear if means FY25 or specific target.

More specific. Assumes new factory operational, tariff normalization, and capacity utilization recovery. Reachable if FTAs operational.

Conservative, but dependent on FTA operationalization (EU FTA Q1 CY27, US ongoing). No hedging disclosed if FTAs delayed.

₹20Cr per factory. First by FY28 (delayed from initial FY27 hint), second by FY30. Phased approach gives flexibility.

Top 5 customers = 70% of revenue; top 10 = >95%. 12–20 customer base is narrow. Loss of 1–2 anchor customers could shrink revenue 20%+.

US tariff headwinds persist; 40% of revenue from USA. Policy reversals or escalation could force additional discounts or lose orders to non-India sources. Management hasn't hedged margin guidance if tariffs worsen.

FY30 guidance (₹500Cr, ₹65Cr PAT) assumes EU FTA (Q1 CY27) and US FTA normalization. Delays or non-operationalization would derail growth plan. No quantified uplift from FTAs disclosed.

Core EBITDA margin only 3.4% in Q1; historically 33% (FY25, excluding exceptional gain). Cost of materials down only 2.3pp YoY. Margin recovery is real but dependent on volume recovery & continued pricing discipline. If tariffs reverse again, margin could contract again.

Patent dispute with SHORTSTOP brand has paused D2C direct-to-consumer vertical (brand name initiative). Test marketing not resumed. Upside margin diversification postponed indefinitely.